Opportunity
Federal Register #2026-20142
FDA renewal of the Antimicrobial Drugs Advisory Committee
Buyer
Department of Health and Human Services / Food and Drug Administration
Posted
October 01, 2026
Identifier
2026-20142
The U.S. Food and Drug Administration is renewing its Antimicrobial Drugs Advisory Committee, a public-interest advisory body rather than a procurement opportunity. - Buyer: U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA). - Purpose: The committee provides independent advice to the FDA Commissioner on the safety and effectiveness of marketed and investigational human drugs for infectious diseases and related disorders. - Expertise: Relevant fields include infectious disease, internal medicine, microbiology, pediatrics, epidemiology, and statistics. - Procurement scope: No products or services are requested, and no OEMs, vendors, quantities, or part numbers are identified.
Description
The Food and Drug Administration announces renewal of the Antimicrobial Drugs Advisory Committee after determining that renewal is in the public interest. The committee advises FDA on the safety and effectiveness of marketed and investigational human drug products for treating infectious diseases and disorders, and makes recommendations to the Commissioner. Its renewed charter will remain in effect until October 7, 2028. The notice also describes committee membership, expertise, and the justification for continuing the committee.